Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM8 | O00222 | 1/20 | 0.51 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.51 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13095825 | 1.00 | GRM8 (0.51) | GRM8GRM4CSNK2A1SMN1; SMN2NOS1 | |
| SCHEMBL4255118 | 0.81 | GRM8 (0.51) | GRM8GRM4CSNK2A1SMN1; SMN2NOS1 | |
| SCHEMBL5029681 | 0.79 | GRM8 (0.47) | GRM8GRM4CSNK2A1SMN1; SMN2NOS1 | |
| Water SCHEMBL11005843 | 0.79 | GRM8 (0.50) | GRM8GRM4CSNK2A1SMN1; SMN2NOS1 | |
| SCHEMBL751985 | 0.75 | GRM8 (0.47) | GRM8GRM4CSNK2A1SMN1; SMN2NOS1 | |
| SCHEMBL28409908 | 0.71 | — | — | |
| SCHEMBL5875737 | 0.69 | — | — | |
| SCHEMBL10074961 | 0.69 | SMN1; SMN2 (0.50) | GRM8GRM4CSNK2A1SMN1; SMN2ALOX15 | |
| SCHEMBL10074960 | 0.69 | SMN1; SMN2 (0.50) | GRM8GRM4CSNK2A1SMN1; SMN2ALOX15 | |
| SCHEMBL7425388 | 0.69 | SMN1; SMN2 (0.50) | GRM8GRM4CSNK2A1SMN1; SMN2ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8168212-B2 | Topical compositions comprising non-proteogenic amino acids and methods of treating skin | AVON PRODUCTS, INC (US) | 2012-05-01 | — | — | US | disclosed |
| US-20100261769-A1 | Topical Compositions Comprising Non-Proteogenic Amino Acids and Methods of Treating Skin | AVON PRODUCTS, INC. (US) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261769-A1 | Topical Compositions Comprising Non-Proteogenic Amino Acids and Methods of Treating Skin | LOXL1, LOXL2, LOXL3 | GRM8 4417/4885GRM4 4727/4885CSNK2A1 965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.